Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03093155 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
A Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 2
- Study locations
NCT03093155 is a Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that has completed, run by Yale University. The registered enrollment target is 78 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03093155, a Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a randomized, two-arm, open-label Phase II multicenter study designed to examine the effects of adding bevacizumab to ixabepilone for the treatment of patients who have recurrent or persistent platinum-resistant/refractory epithelial (non-mucinous) ovarian, fallopian tube, or primary peritoneal cancer. Its primary objective is to assess whether adding bevacizumab to ixabepilone improves progression-free survival in its target population. Study participants will be stratified by (a) study site and (b) previous receipt of bevacizumab prior to randomization.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Ixabepilone
Study Locations (2)
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
Maryland
- Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2017-04-03 |
| Est. Completion | 2022-12-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03093155
The ClinicalTrials.gov registry entry for NCT03093155 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (69% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT03093155 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, Maryland.
Frequently Asked Questions
What is clinical trial NCT03093155 about?
NCT03093155 is a clinical study titled "Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab". This is a randomized, two-arm, open-label Phase II multicenter study designed to examine the effects of adding bevacizumab to ixabepilone for the treatment of patients who have recurrent or persistent platinum-resistant/refractory epithelial (non-mucinous) ovarian, fallopian tube, or primary periton...
What is the current status of trial NCT03093155?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2017-04-03. Estimated completion is 2022-12-29.
What conditions does trial NCT03093155 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Cancer.
What interventions are being tested in trial NCT03093155?
The interventions under investigation include: Bevacizumab (DRUG), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT03093155?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03093155 being conducted?
This trial has 2 study locations across Connecticut, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.